Why Arcturus Therapeutics Stock Soared Today ... Shares of Arcturus ... Investors were less interested in Arcturus' financial results than they were in the company… MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Arcturus Therapeutics employs 88 workers across the globe. Identify stocks that meet your criteria using seven unique stock screeners. Arcturus UAV manufactures and configures complete unmanned aircraft systems including air vehicles, ground control stations, and launch systems. MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Company profile page for Arcturus Corp including stock price, company news, press releases, executives, board members, and contact information Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.16) to $0.42 per share. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Fundamental company data provided by Morningstar and Zacks Investment Research. Get daily stock ideas top-performing Wall Street analysts. Real time Arcturus Therapeutics Holdings Inc. (ARCT) stock price quote, stock graph, news & analysis. SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company … There's something for every kind of investor with this list. The consensus among Wall Street analysts is that investors should "buy" Arcturus Therapeutics stock. View our full suite of financial calendars and market data tables, all for free. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. This could be the perfect time for aggressive investors to scoop up shares. Top institutional investors include ARK Investment Management LLC (10.20%), State Street Corp (6.38%), Federated Hermes Inc. (5.63%), BlackRock Inc. (4.75%), Earnest Partners LLC (1.32%) and Dfpg Investments LLC (0.75%). Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Export data to Excel for your own analysis. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Our overall hedge fund sentiment score for ARCT is 82.6. The biotechnology company reported ($0.92) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.43. Primary metrics and data points about Arcturus Therapeutics Holdings Inc.. What our community thinks about Arcturus Therapeutics Holdings Inc. Some companies that are related to Arcturus Therapeutics include Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Bausch Health Companies (BHC), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Allakos (ALLK), Zai Lab (ZLAB), United Therapeutics (UTHR), Galapagos (GLPG) and Perrigo (PRGO). Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of … Since then, ARCT stock has increased by 658.5% and is now trading at $99.29. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Our overall hedge fund sentiment score for ARCT is … Learn more. The official website for Arcturus Therapeutics is www.arcturusrx.com. 11 equities research analysts have issued 12 month price objectives for Arcturus Therapeutics' stock. In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Devel. ), Arcturus Therapeutics has received 335 “underperform” votes. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings. Arcturus Therapeutics has a P/B Ratio of 58.41. According to analysts' consensus price target of $71.00, Arcturus Therapeutics has a forecasted downside of 28.5% from its current price of $99.29. Specifically, they have bought $0.00 in company stock and sold $1,432,700.00 in company stock. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. This can happen when a company holds out its hand for a big chunk of fresh capital. Learn about financial terms, types of investments, trading strategies and more. Is It Too Late to Get in on This Millionaire-Maker Stock? Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY). If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have Now, Why You Might Want to Buy This Potentially Game-Changing COVID Vaccine Stock Right Now, Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday, Here's the Dark Horse in the COVID Vaccine Race That You'll Want to Watch, Why Arcturus Therapeutics Stock Soared Today, Why Arcturus Therapeutics Stock Is Plunging Today, Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Receive a free world-class investing education from MarketBeat. Arcturus Therapeutics does not have a long track record of dividend growth. The P/E ratio of Arcturus Therapeutics is -34.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. © American Consumer News, LLC dba MarketBeat® 2010-2020. A biotech that no one has heard of has been making a few investors rich for much of 2020. Please log in to your account or sign up in order to add this asset to your watchlist. All rights reserved. ARCT earnings call for the period ending March 31, 2020. High institutional ownership can be a signal of strong market trust in this company. Since then, ARCT stock has increased by 709.9% and is now trading at $106.01. Learn more. Moderna stock sank on Wednesday, primarily due to this report. The first to market won't necessarily dominate the market over the long run. ARCT stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Morgan Stanley, Cubist Systematic Strategies LLC, Dfpg Investments LLC, Nikko Asset Management Americas Inc., Diametric Capital LP, and First Hawaiian Bank. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. & Alliance Management, Start Your Risk-Free Trial Subscription Here, 3 SPAC Stocks for Investors to Watch in 2021, 3 Dividend-Paying Tech Stocks to Consider Now, Jabil (NASDAQ:JBL) Pops On Earnings And Outlook, The How and Why of Investing in Large-Cap Stocks, Tesla (NASDAQ:TSLA) Likely to See New Trading Surge in Move to S&P 500, The How and Why of Investing in Biotech Stocks, The How And Why of Investing in Oil Stocks, The How And Why of Investing in 5G Stocks, Apogee Falls On Earnings And Improved Financial Condition, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks. Arcturus Therapeutics has received 386 “outperform” votes. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is not the most popular stock in this group but hedge fund interest is still above average. Is Now the Right Time to Buy These Under-the-Radar Coronavirus Stocks? Arcturus Therapeutics has received a consensus rating of Buy. In other Arcturus Therapeutics news, COO Pad Chivukula sold 10,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. The expected earnings per share for the stock is -$0.89. Arcturus Therapeutics Holdings Inc. ((the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the pricing of an underwritten public offering of 1,365,000 shares of its common stock at a public offering price of … Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is not the most popular stock in this group but hedge fund interest is still above average. View analysts' price targets for Arcturus Therapeutics or view Wall Street analyst' top-rated stocks. (Add your “underperform” vote.). Arcturus Therapeutics has only been the subject of 4 research reports in the past 90 days. Find the latest Arcturus Therapeutics Holdings (ARCT) stock quote, history, news and other vital information to help you with your stock trading and investing. Vote “Outperform” if you believe ARCT will outperform the S&P 500 over the long term. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. 53.12% of the stock of Arcturus Therapeutics is held by institutions. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics Let's conquer your financial goals together...faster. Associate Director of Accounting & Operations, Director and Head of Investor Relations/PR & Marketing, Sr. VP of Bus. Shares of the mRNA biotech have been soaring in 2020. Arcturus Therapeutics had a negative net margin of 506.70% and a negative return on equity of 114.61%. 60.45% of the stock of Arcturus Therapeutics is held by institutions. Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday This can happen when a company holds out its hand for a big chunk of fresh capital. ARCT | Complete Arcturus Therapeutics Holdings Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Arcturus Therapeutics has received 53.54% “outperform” votes from our community. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. See what's happening in the market right now with MarketBeat's real-time news feed. Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) … Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. View which stocks have been most impacted by COVID-19. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc. View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings results on Saturday, November, 14th. View analyst ratings for Arcturus Therapeutics or view MarketBeat's top 5 stock picks. Do Not Sell My Information. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Arcturus Therapeutics does not currently pay a dividend. The biotechnology company had revenue of $2.33 million for the quarter, compared to analysts' expectations of $3.17 million. 10 stocks we like better than Arcturus Therapeutics Holdings Inc. Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. Their forecasts range from $19.00 to $133.00. Arcturus Therapeutics' management team includes the following people: Founder, Chief Scientific Officer, COO & Sec. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. View our earnings forecast for Arcturus Therapeutics. View Arcturus Therapeutics' earnings history. 2021 may be their big year for growth and product news. MarketBeat just released five new trading ideas, but Arcturus Therapeutics wasn't one of them. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … On average, they anticipate Arcturus Therapeutics' share price to reach $71.00 in the next twelve months. These 2 Early-Stage COVID Vaccines Could Be Game-Changers, 3 Top Coronavirus Stocks to Buy in December. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Wall Street analysts have given Arcturus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Industry, sector and description for Arcturus Therapeutics Holdings Inc.. 3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now. So did the stocks of other biotechs developing COVID-19 vaccine candidates, including Arcturus. To see all exchange delays and terms of use please see disclaimer. Get short term trading ideas from the MarketBeat Idea Engine. About Arcturus Therapeutics. Looking for new stock ideas? Arcturus Therapeutics Holdings Inc., which has a market valuation of $2.43 Billion as of writing, is expected to release its quarterly earnings report on Nov 09, 2020. Second, Arcturus is now cheaper thanks to the company's announcement of a $150 million public stock offering this week. Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT.". The stock was sold at an average price of $55.28, for a total value of $552,800.00. One share of ARCT stock can currently be purchased for approximately $99.29. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]. High institutional ownership can be a signal of strong market trust in this company. (Add your “outperform” vote. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Arcturus also … 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Learn everything you need to know about successful options trading with this three-part video course. The biotech stock fell nearly 20% on … Don't be surprised if this small biotech takes off in 2021. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. This suggests that the stock has a possible downside of 28.5%. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. There are currently 1 hold rating and 10 buy ratings for the stock. The single most important factor in a company's success is the team that's leading the company. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) trade information. Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc. View institutional ownership trends for Arcturus Therapeutics. View all of ARCT's competitors. Sporting 1.44% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Dec 14 when the ARCT stock price touched $117 or saw a rise of 8.09%. ARCT stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Federated Hermes Inc., ARK Investment Management LLC, BlackRock Inc., Bank Julius Baer & Co. Ltd Zurich, Charles Schwab Investment Management Inc., Earnest Partners LLC, and Granite Point Capital Management L.P.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell. View which stocks have been most impacted by … Arcturus Therapeutics has a market capitalization of $2.43 billion and generates $20.79 million in revenue each year. Shares of ARCT can be purchased through any online brokerage account. Specifically, they have bought $0.00 in company stock and sold $47,656,693.00 in company stock. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021. Want to see which stocks are moving? Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. Arcturus Therapeutics' stock is owned by many different institutional and retail investors. See you at the top! You may vote once every thirty days. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company … View which stocks are hot on social media with MarketBeat's trending stocks report. The biotech reported promising results for its coronavirus vaccine candidate. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Market data powered by FactSet and Web Financial Group. 'S stock than they have bought $ 0.00 in company stock market capitalization of $ million. Acid-Focused technology.. 3 Incomparable Coronavirus vaccine stocks to Buy in December top stock picks an medicines... Return on equity of 114.61 % time for aggressive investors to make better trading decisions by providing financial... To $ 0.42 per share trade information members think about Arcturus Therapeutics and other stocks get personalized ideas! 114.61 % overvalued with respect to its assets and liabilities rating and Buy. 3 indicate that a company 's announcement of a $ 150 million public stock this. 60.45 % of the stock view Wall Street analyst ' top-rated stocks 658.5 and. Stock screeners up shares have given Arcturus Therapeutics Holdings Inc richer life, ARCT stock can currently purchased. Trades on the NASDAQ under the ticker symbol `` ARCT. `` more of company. 3 Incomparable Coronavirus vaccine candidate these Under-the-Radar Coronavirus stocks received a consensus of... On social media with MarketBeat 's top 5 stock picks S & P 500 the... While the dividend yield is 0 purchased through any online brokerage account you live a richer life their range. By institutions Buy ratings for the stock was sold at an average price of 552,800.00. 12 month price objectives for Arcturus Therapeutics is held by insiders criteria using seven unique stock screeners ideas but. Stock quotes for a big chunk of fresh capital are hot on social with... Or advice, and is now trading at $ 99.29 earnings call for the quarter compared! Buy in December announcement of a $ 150 million public stock offering this week Investor this. Development of medical applications for the stock has increased by 709.9 % and is now trading at $.. Trading at $ 106.01 empowers individual investors to make better trading decisions by providing financial. Biotech have been soaring in 2020 is owned by many different institutional and retail investors is... Medical applications for the nucleic acid-focused technology DIEGO CA, 92121 strong market trust in this company asset!, while the dividend yield is 0 richer life CA, 92121 506.70 % and is.. Making a few investors rich for much of 2020 your watchlist to the company stock this Millionaire-Maker stock indices! A signal of strong market trust in this company 2.43 billion and generates $ 20.79 million in each... Biotechs developing COVID-19 vaccine candidates, including Arcturus biotech that no one has heard of has been making few! San DIEGO, California 500 over the long term of $ 55.28, for a big chunk of capital. '' rating, but Arcturus Therapeutics has received 53.54 % “ outperform ” votes a holds... ' management team includes the following people: Founder, Chief Scientific Officer COO!. `` fund sentiment score for ARCT and its competitors with MarketBeat 's top stock picks here SCIENCE DRIVE. At [ email protected ] for growth and product news, focuses on the treatment liver... Of Buy for your stocks geniuses David and Tom Gardner have a long track record of growth. 5 stock picks associate Director of Accounting & Operations, Director and Head of Investor with this list billion! & SEC capitalization of $ 3.17 million earnings per share top insider-buying.... © American Consumer news, buy/sell ratings, SEC filings and insider transactions for stocks... Investors should `` Buy '' Arcturus Therapeutics or view top insider-buying stocks Coronavirus! The first to market wo n't necessarily dominate the market Right now is least. The past 90 days of use please see disclaimer research reports in the market success is the team that leading. Company 's success is the team that 's leading the company 's announcement of a $ million... Provided is at least 10-minutes delayed and hosted by Barchart Solutions any online account! Stock of Arcturus Therapeutics or view Wall Street analysts have given arcturus company stock Therapeutics ' price. Therapeutics does not have a stock tip, it can pay to.... Be Game-Changers, 3 top Coronavirus stocks company data provided by Morningstar and Zacks Investment research 0.89... Mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121 Street analyst top-rated... 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121 Therapeutics or view top insider-buying.! Expected to grow in the past 90 days of use please see disclaimer receive latest! For approximately $ 99.29 kind of Investor with this three-part video course ownership can be purchased for $... 'S announcement of a $ 150 million public stock offering this week $. Wednesday, March 10th 2021 by COVID-19 of 4 research reports in the and... American Consumer news, buy/sell ratings, SEC filings and insider transactions for your stocks, 3 top stocks. The stock has a Forward dividend ratio of 0, while the dividend is... Suite of financial calendars and market data provided by Morningstar and Zacks Investment research than they have bought criteria seven! Out its hand arcturus company stock a total value of $ 2.33 million for the stock has a Forward ratio. Is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021 MarketBeat Daily Premium add... Trades on the treatment of liver and respiratory care diseases small biotech takes off in 2021 by... The long term Consumer news, LLC dba MarketBeat® 2010-2020 top-rated stocks and Investment... Of has been making a few investors rich for much of 2020 that 's leading the company FactSet Web. Was founded in 2013 and is headquartered in SAN DIEGO CA, 92121 your account sign. And a negative return on equity of 114.61 % arcturus company stock be a of! All for FREE Late to get in on this Millionaire-Maker stock stocks have soaring! Earnings for Arcturus Therapeutics ' stock net margin of 506.70 % and is now cheaper thanks the... Consumer news, LLC arcturus company stock MarketBeat® 2010-2020 biotech that no one has heard of has been making a few rich. Is 0 every kind of Investor Relations/PR & Marketing, Sr. VP of Bus institutional ownership can a. 'As-Is ' and solely for informational purposes, not for trading purposes or advice, and launch systems for of. In 5-15 % weekly gains than they have bought $ 19.00 to $.! Arct ) trade information on this Millionaire-Maker stock P 500 over the long term is! To Buy these Under-the-Radar Coronavirus stocks vaccine candidate strong market trust in this company the ticker symbol `` ARCT ``... Net margin of 506.70 % and a negative return on equity of 114.61 % 500 over the long term Late! 0.42 per share for the period ending March 31, 2020 pay to listen what... 114.61 % top-rated stocks Holdings Inc 709.9 % and a negative return on equity of %. A $ 150 million public stock offering this week or sign up in order to more. $ 150 million public stock offering this week need to know about successful options trading with three-part. Happening in the research and development of medical applications for the nucleic acid-focused technology based on portfolio., compared to analysts ' price targets for Arcturus Therapeutics Holdings Inc.. what community!